A first patient has been dosed in IMAC Holdings’ Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson’s disease.

The infusion treatment was given on Dec. 29, 2020, by the trial’s lead investigator Ricardo Knight, MD, at IMAC’s facility in Brentwood, Tennessee, the company announced.

html, body { height:100%; width:100%; margin:0; padding:0;
}
.element-is-sticky { -moz-animation: cssAnimation 0s ease-in 2s forwards; /* Firefox */ -webkit-animation: cssAnimation 0s ease-in 2s forwards; /* Safari and Chrome */ -o-animation: cssAnimation 0s ease-in 2s forwards; /* Opera */ animation: cssAnimation 0s ease-in 2s forwards; -webkit-animation-fill-mode: forwards; animation-fill-mode: forwards;
}
@keyframes cssAnimation { to { width:0; height:0; overflow:hidden; }
}
@-webkit-keyframes cssAnimation { to { width:0; height:0; visibility:hidden; }
}

“The first infusion of our proprietary compound is a significant milestone in its development, as well as in the development of IMAC, expanding our capabilities as a regenerative rehabilitation company,” said Jeffrey Ervin, IMAC’s CEO.

Bradykinesia is characterized by slowness or difficulty in movement and is one of the early signs of Parkinson’s disease. Although the mechanisms resulting in bradykinesia remain unclear, an inflammatory component seems to be involved.

<!–

–> #post-32585{padding:0;} html, body { height:100%; width:100%; margin:0; padding:0;
}
.element-is-sticky { -moz-animation: cssAnimation 0s ease-in 3s forwards; /* Firefox */ -webkit-animation: cssAnimation 0s ease-in 3s forwards; /* Safari and Chrome */ -o-animation: cssAnimation 0s ease-in 3s forwards; /* Opera */ animation: cssAnimation 0s ease-in 3s forwards; -webkit-animation-fill-mode: forwards; animation-fill-mode: forwards;
}
@keyframes cssAnimation { to { width:0; height:0; overflow:hidden; }
}
@-webkit-keyframes cssAnimation { to { width:0; height:0; visibility:hidden; }
}

Stem cells, due to their capacity to continuously divide and differentiate into various cell types, have gained interest as potential treatments in different areas, including as a regenerative medicine for neurological disorders such as Parkinson’s.

MSCs are a type of adult stem cell found in multiple tissues, including the umbilical cord, bone marrow, and fat. Because of its anti-inflammatory properties, MSCs may help to treat bradykinesia by modulating the immune system and easing inflammation.

IMAC’s open-label trial (NCT04385056) is evaluating the safety and tolerability of escalating doses of allogeneic mesenchymal stem cells to treat patients with bradykinesia. Unlike autologous stem cells that are collected from a patient’s own tissues, allogeneic stem cells are derived from a healthy donor, and used to replace a person’s diseased or damaged cells.

The trial aims to enroll 15 Parkinson’s patients, ages 55 or older, who have been experiencing bradykinesia for at least three months before enrollment. Patients can be on a stable levodopa or other standard treatment dose.

#post-32585{padding:0;} html, body { height:100%; width:100%; margin:0; padding:0;
}
.element-is-sticky { -moz-animation: cssAnimation 0s ease-in 3s forwards; /* Firefox */ -webkit-animation: cssAnimation 0s ease-in 3s forwards; /* Safari and Chrome */ -o-animation: cssAnimation 0s ease-in 3s forwards; /* Opera */ animation: cssAnimation 0s ease-in 3s forwards; -webkit-animation-fill-mode: forwards; animation-fill-mode: forwards;
}
@keyframes cssAnimation { to { width:0; height:0; overflow:hidden; }
}
@-webkit-keyframes cssAnimation { to { width:0; height:0; visibility:hidden; }
}

Participants will be randomly assigned to one of three dose groups — low, medium or high — and treated with a single intravenous (into the vein) infusion. Patients will then be followed for 12 months by IMAC doctors and physical therapists.

The still-enrolling study is being conducted at three of IMAC’s clinical centers: Chesterfield, Missouri; Paducah, Kentucky; and Brentwood. Contact and other information can be found here.

“We have already received significant interest from patients across our regenerative medicine centers to participate in the trial, and we are actively screening these inquiries to identify those who fit the inclusion criteria of the trial. We anticipate full patient enrollment by the end of February 2021, with subsequent infusions continuing in early 2021,” Ervin said.

Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia
Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.
Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia
Total Posts: 208
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia
Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.
Latest Posts

.uab-field i, .uab-num-post-count {display:none;}
.uab-template-2 .uab-contact-form-submit input[type=submit] { padding: 17px 25px 30px; margin-top: 2em;
}
.uab-template-2 .uab-tabs li.uab-current { background: #4C9FFD;} .uab-template-2 .uab-tabs a, .uab-template-2 .uab-tabs li {color: #4C9FFD;} .uab-template-2 .uab-tabs li:after { border-color: #4C9FFD transparent transparent transparent;
}

Read original article here.